Purpose: Weekly dose-dense paclitaxel (PTX) in combination with carboplatin (CBDCA) every 3 weeks (ddTC therapy) is a standard treatment for patients with advanced ovarian cancer. However, there is no detailed analysis of the feasibility of ddTC therapy in elderly patients with ovarian cancer.
Methods: We identified patients diagnosed with ovarian, fallopian tube, or peritoneal cancer who received ddTC therapy at the National Cancer Center Hospital from April 2003 to April 2013. We assessed the feasibility of ddTC therapy in elderly patients aged 70 years or older (elderly group), comparing relative dose intensity (RDI) for PTX, CBDCA, and ddTC; adverse events; and rate of chemotherapy discontinuation to those in patients below 70 years of age (younger group).
Results: A total of 143 patients (elderly group, 22; younger group, 121) was analyzed. A comparison of RDI between these two groups showed no significant differences for PTX, CBDCA, and ddTC. Nonhematological and hematological toxicity profiles of the elderly and younger groups were similar, except that severe peripheral neuropathy (Grade 2 or higher) was more common in the elderly group. There was no significant difference in the rate of chemotherapy discontinuation (elderly group, 13.6 % vs. younger group, 7.4 %, p = 0.397).
Conclusions: Our study showed that ddTC therapy was feasible for elderly patients. However, to prevent severe neuropathy, PTX dose reduction deserves consideration.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00280-016-3100-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A single institutional clinical outcome for stages III and IV ovarian cancer patients treated with dose-dense TC therapy in the frontline or first platinum-sensitive relapse setting.
J Obstet Gynaecol Res
September 2024
Department of Obstetrics and Gynecology, Yamaguchi University Graduate school of Medicine, Minami-Kogushi, Japan.
Article Synopsis
- Dose-dense paclitaxel/carboplatin (ddTC) therapy was initially thought to be more effective for treating ovarian cancer than the traditional tri-weekly TC, based on the JGOG3016 study, although later studies showed mixed results.
- A retrospective analysis of patients treated with ddTC from 2012 to 2018 revealed high response rates (RRs) and progression-free survival (PFS) times, with front-line treatment achieving an RR of 82.9% and a median PFS of 20 months.
- Overall, ddTC therapy showed strong effectiveness in managing advanced stages (III and IV) of ovarian cancer, providing promising outcomes for both first-line and platinum-sensitive relapse treatments.
Therapeutic effect of dose-dense paclitaxel plus carboplatin with or without bevacizumab for Japanese patients with epithelial ovarian cancer.
Int J Clin Oncol
September 2024
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Minato-Ku, Tokyo, 105-8461, Japan.
Background: Evidence regarding chemosensitivity to different therapeutic regimens in epithelial ovarian cancer (EOC) remains limited. This study aimed to investigate EOC implementation in daily clinical practice and reveal favorable regimens for EOC among Japanese patients.
Methods: We retrospectively collected clinical data of patients newly diagnosed with EOC from 2012 to 2021 at our affiliated institutions.
Enhanced localized therapeutic precision: A face-to-face folate-targeted Cu-mediated nanotherapy with thermosensitive sustained-release system.
Int J Pharm
June 2024
School of Pharmaceutical Sciences, Shenyang Pharmaceutical University, No. 103, Wenhua Road, Shenyang 110016, China. Electronic address:
Article Synopsis
- The study developed a biodegradable hydrogel that co-delivers disulfiram (DSF) and folate-modified liposomes containing copper (Cu) to enhance targeted cancer treatment for peritoneal carcinoma.
- The unique hydrogel allows for sustained and pH-sensitive release of Cu in tumor environments, optimizing the therapeutic effects while minimizing toxicity.
- Experimental results demonstrated that this approach significantly increased tumor inhibition in mice, with the dual-nanocarrier system showing higher effectiveness compared to non-targeted treatments.
A retrospective study of dose-dense paclitaxel and carboplatin plus bevacizumab as first-line treatment of advanced epithelial ovarian cancer.
J Gynecol Oncol
November 2024
Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.
Article Synopsis
- The study aimed to compare the effectiveness, safety, and tolerability of a treatment combining dose-dense paclitaxel and carboplatin with bevacizumab (ddTC+Bev) versus dose-dense paclitaxel and carboplatin alone (ddTC) for advanced ovarian cancer.
- A total of 134 patients treated with either ddTC+Bev or ddTC were analyzed, showing that the ddTC+Bev group had better progression-free survival (PFS) at first glance, but the results were less significant when adjusted for potential biases.
- The study concluded that there wasn't enough evidence to prove that adding bevacizumab improves patient outcomes, indicating the need for further research with larger
Development of Hollow Gold Nanoparticles for Photothermal Therapy and Their Cytotoxic Effect on a Glioma Cell Line When Combined with Copper Diethyldithiocarbamate.
Biol Pharm Bull
January 2024
Drug Delivery and Nano Pharmaceutics, Graduate School of Pharmaceutical Sciences, Nagoya City University.
Gold-based nanoparticles hold promise as functional nanomedicines, including in combination with a photothermal effect for cancer therapy in conjunction with chemotherapy. Here, we synthesized hollow gold nanoparticles (HGNPs) exhibiting efficient light absorption in the near-IR (NIR) region. Several synthesis conditions were explored and provided monodisperse HGNPs approximately 95-135 nm in diameter with a light absorbance range of approximately 600-720 nm.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!